1. Life Sciences

Take Care When Paying Volume-Based Compensation to Sales Agents to Avoid Anti-Kickback Statute Violations – Duane Morris Life Sciences Law

Written by Posted on Less than 0 min read




By  Frederick R. Ball, Coleen W. Hill and Victoria (Tori) Hawekotte

Pharmaceutical companies sometimes compensate sales agents per volume sold. The Fifth and Seventh Circuits have indicated that a company may structure such arrangements without running afoul of the Anti-Kickback Statute (AKS). However, such arrangements carry risk of violating the AKS and should be structured with care.

Read the full story on the Duane Morris LLP website.



Member since

More from Duane Morris

  1. Life Sciences

Federal Trade Commission Poised to File Suit Against Pharmacy Benefit Managers Based on Unlawful Medication Pricing – Duane Morris Life Sciences Law

On July 10, 2024, multiple media sources reported that the Federal Trade Commission intends to file suit against the nation’s three largest pharmacy benefit managers over​ allegations of improper pricing in connection with their negotiations with drug manufacturers that dramatically increased prices for consumers and lined the PBMs’ pockets with lucrative […]
Written by
  1. Life Sciences

Doing No Harm but Exporting Without Appropriate License Can Violate Regulations – Duane Morris Life Sciences Law

By Brandon A. Chan, Ph.D., and Brian Goldstein On June 24, 2024, the Department of Commerce’s Bureau of Industry and Service (BIS) imposed an administrative penalty on Indiana University (IU) as part of a settlement agreement following IU’s discovery and self-disclosure to BIS that its Bloomington Drosophila Stock Center engaged in the export of materials […]
Written by
  1. Life Sciences

Federal Court Grants EPA Request to Stay Litigation Challenging 2024 Ethylene Oxide Regulation Pending Agency’s Reconsideration

By Sharon L. Caffrey, Jeffrey S. Pollack and Coleen W. Hill In June 2024, industry and environmentalist parties filed a petition in the U.S. Court of Appeals for the District of Columbia Circuit for review of a national emission standards for hazardous air pollutants regulation applicable to commercial sterilization facilities, which was […]
Written by
  1. Life Sciences

How They’ll Have an effect on Patent Prosecution Methods – Duane Morris Life Sciences Legislation

The USPTO is soliciting feedback relating to its proposed charge will increase for fiscal yr 2025. Written feedback have to be acquired on or earlier than June 3, 2024, to make sure consideration. Thus, it’s essential that each in-house attorneys and outdoors counsel assessment and contemplate how these adjustments, a few […]
Written by
  1. Life Sciences

Federal Court Enjoins Enforcement of NIH’S Rate Change Notice Regarding Indirect Costs – Duane Morris Life Sciences Law

By Dan Walworth, Rolando Sanchez, Frederick Ball, Geoffrey Goodale and Sara Smith Since taking office, the Trump Administration has taken steps to reshape the United States’ federal funding infrastructure. One such action relates to the National Institutes of Health’s (“NIH”) rate change, imposing a 15% cap for indirect costs, for new grants and for existing […]
Written by
  1. Life Sciences

FDA Drafts Guidance on Pre-market Submissions for Patient-Matched Guides to Orthopedic Implants – Duane Morris Life Sciences Law

This summer, the U.S. Food and Drug Administration (FDA) issued draft guidance regarding patient-matched guides to orthopedic implants, which are intended to assist in the execution of a pre-surgical plan concurred upon by the patient’s healthcare professional to position an orthopedic implant in a way consistent with the implant’s indicated use. In […]
Written by
  1. Life Sciences

FDA’s Latest Draft Guidance on Medical Device PCCPs Incorporates FD&C Act Changes – Duane Morris Life Sciences Law

The U.S. Food and Drug Administration (FDA) recently issued draft Guidance informing medical device manufacturers how to structure a predetermined change control plan (PCCP) to describe appropriate, intended future device modifications. The Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research in consultation with the Center for Drug […]
Written by
  1. Life Sciences

FDA Issues Draft Guidance Q&A on Developing Potential Cellular and Gene Therapy Products – Duane Morris Life Sciences Law

In November 2024, the U.S. Food and Drug Administration (FDA) issued draft Guidance responding to frequently asked questions about developing cellular and gene therapy (CGT) products. This draft Guidance supplements existing finalized and draft Guidance on CGT products. Read the full Alert on the Duane Morris LLP Website. Duane Morris Member since […]
Written by
  1. Life Sciences

Artificial Intelligence in Medtech – Duane Morris Life Sciences Law

Given the vast amounts of data available, including raw measurements, diagnostic information, treatment plans, and regulatory guidelines, the biomedical technologies sector stands to gain immensely from artificial intelligence (AI), particularly machine learning (ML). ML, at its core, learns from training datasets to identify patterns, which can then be applied to new […]
Written by
  1. Life Sciences

Montana Set to Become a “Wild West” Hub for Experimental Medical Treatments and Therapies – Duane Morris Life Sciences Law

By Vicki G. Norton, Ph.D., and Brandon A. Chan Ph.D. The Federal Food, Drug and Cosmetic Act generally prohibits access to investigational drugs that have not yet been approved by the United States Food and Drug Administration. Patients that have been diagnosed with a life-threatening or seriously debilitating disease may request […]
Written by
  1. Life Sciences

FDA’s New Rule Regulates Lab-Developed Tests Under FD&C Act – Duane Morris Life Sciences Law

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule that amends existing regulations to make explicit that in vitro diagnostic products and tests (IVDs), including laboratory developed tests (LDTs), are devices regulated under the Federal Food, Drug and Cosmetic Act (FD&C Act). LDTs have increased in volume, complexity and […]
Written by
  1. Life Sciences

House Oversight Committee Gives Pharmacy Benefit Managers Deadline to Correct Congressional Record of Allegedly Fraudulent Statements

On August 28, 2024, the U.S. House Committee on Oversight and Accountability issued letters to executives of three of the nation’s largest pharmacy benefit managers (PBMs), accusing them of providing false testimony before Congress. Each letter outlines the allegedly false statements and the evidence that the statements contradict. They also outline […]
Written by
  1. Life Sciences

FDA Pushes Back Enforcement Deadline for MoCRA Facility Registration and Product Listing Requirements – Duane Morris Life Sciences Law

Today, FDA announced updated guidance regarding its MoCRA rollout. FDA  does not intend to enforce the requirements related to cosmetic product facility registration and cosmetic product listing for an additional six months after the December 29, 2023, statutory deadline, or until July 1, 2024, to provide regulated industry additional time to comply with these requirements. To […]
Written by
  1. Life Sciences

FDA Confirms No Asbestos in Beauty Talc Merchandise for a Third 12 months in 2023 – Duane Morris Life Sciences Legislation

On April 5, 2024, the U.S. Meals and Drug Administration (FDA) confirmed that its third-party testing of beauty talc merchandise for 2023 recognized no traces of asbestos in any of the 50 beauty samples examined. FDA’s 2023 outcomes, which had been reported in a Cosmetics Constituent Replace, are per its testing for 2022 and 2021, which […]
Written by
  1. Life Sciences

What Spas Need to Know – Duane Morris Life Sciences Law

The global market for intimate wellness products is expected to grow to $81.4 billion by 2028, up from $51.9 billion in 2021, according to recent market research reports. Once taboo, or the topic of hush-hush conversations, intimate wellness brands are increasingly crossing over into mainstream wellness marketing, collaborating with well-known fashion […]
Written by
  1. Life Sciences

The Changing Beauty Regulatory Landscape – Duane Morris Life Sciences Law

Duane Morris attorney Kelly Bonner was quoted in an article in WWD on June 25, 2024. “A big deadline in the beauty and personal care regulatory landscape is fast approaching, with much more to come — although some experts believe this still isn’t enough. Under the Modernization of Cosmetics Regulation Act, or MoCRA, passed […]
Written by
  1. Life Sciences

Federal Regulatory Laws Due Overhaul after MoCRA – Duane Morris Life Sciences Law

On December 23, 2022, Congress enacted the Modernization of Cosmetics Regulation Act (MoCRA)—the first major statutory change to the U.S. federal government’s ability to regulate cosmetics since 1938. Passed with bipartisanand industry support, MoCRA expands the Food and Drug Administration’s authority over cosmetics, and creates substantial new obligations for manufacturers, packers […]
Written by
  1. Life Sciences

Rick Ball and Coleen Hill to Speak at MassMEDIC Regulatory Roundup – Duane Morris Life Sciences Law

Duane Morris attorneys Rick Ball and Coleen Hill will be speakers at MassMEDIC’s Regulatory Roundup, to be held on November 15, 2023 from 8:00 a.m. to 4:15 p.m.  Rick and Coleen will present “When Things Go Wrong: Navigating Enforcement When the FDA, SEC, and DOJ Are All Involved.” For more information […]
Written by
  1. Life Sciences

Neighborhood Pharmacists Demand CMS Take Enforcement Motion Towards PBMs – Duane Morris Life Sciences Legislation

As information surfaced on February 27 that Congress is punting long-debated pharmacy profit supervisor reforms, the neighborhood pharmacy foyer demanded CMS instantly take enforcement motion in opposition to improper PBM practices that the foyer says may trigger almost a 3rd of impartial pharmacies to shutter this yr. […] Jonathan Swichar, associate […]
Written by
  1. Life Sciences

Obviousness-Type Double Patenting Immunity for First-Filed, First-Issued and Later-Expiring Patent in a Family – Duane Morris Life Sciences Law

Recently, the relationship and intersection between obviousness-type double patenting (ODP) and any awarded Patent Term Adjustment (PTA) and/or Patent Term Extension (PTE) has received significant attention. The United States Court of Appeals for the Federal Circuit held in In re Cellect, 81 F.4th 1216 (Fed. Cir. 2023), that PTA and PTE, being codified […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: Take Care When Paying Volume-Based Compensation to Sales Agents to Avoid Anti-Kickback Statute Violations – Duane Morris Life Sciences Law

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.